JSKN-003

Alphamab Oncology's JSKN003, an anti-HER2 bispecific ADC, enters Phase III trial for platinum-resistant recurrent ovarian cancer, comparing its efficacy against chemotherapy.

Alphamab Oncology's JSKN033, a subcutaneous co-formulation of anti-HER2 bispecific ADC and PD-L1 inhibitor, has been included in Shanghai's pilot program for innovative drug clinical trials.

Alphamab Oncology's JSKN033, a subcutaneous co-formulation of anti-HER2 bispecific ADC and PD-L1 inhibitor, has been included in Shanghai's pilot program for accelerated clinical trial review.

JSKN003 demonstrated a 56.8% objective response rate in heavily pretreated patients with platinum-resistant ovarian cancer, irrespective of HER2 expression.

JSKN003, an anti-HER2 bispecific antibody-drug conjugate, shows a 56.8% objective response rate in heavily pretreated platinum-resistant ovarian cancer patients.